Advertisement

Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications

Published:March 06, 2019DOI:https://doi.org/10.1016/j.ejca.2018.11.033

      Highlights

      • Statin users had lower risk of metastatic prostate cancer (PC) and PC mortality.
      • Non-statin lipid-lowering medication use showed similar associations as statins.
      • Cholesterol lowering seems to be the protective mechanism against advanced PC.

      Abstract

      Background

      Statins have demonstrated protection against aggressive/late-stage and/or lethal prostate cancer (PC), but prior studies are limited by small populations, short follow-up and unequal health-care access. Research has not demonstrated that non-statin lipid-lowering medications (NSLLMs) provide a similar benefit, which would support a cholesterol-based mechanism. We sought to rigorously test the hypothesis that cholesterol-lowering drugs affect PC incidence and severity.

      Methods

      A retrospective cohort study was conducted by abstracting prescription and health service records for 249,986 Saskatchewan men aged ≥40 years between January 1, 1990 and December 31, 2014 and comparing first-time statin and NSLLM users with age-matched non-users and glaucoma medication (GM) users for PC incidence, metastases at diagnosis and PC mortality using Cox proportional hazards regression.

      Results

      In comparing statin users to non-users, a weak association was detected with increased PC incidence (hazard ratio [HR] 1.07, 95% confidence interval [CI]: 1.02–1.12) that disappeared when compared with GM users. Substantial protective associations were observed between statin use and metastatic PC and PC mortality (HRs 0.69, 95% CI: 0.61–0.79 and 0.73, 95% CI: 0.66–0.81, respectively), which were stronger when compared with GM use (HRs 0.52, 95% CI: 0.40–0.68 and 0.51, 95% CI: 0.41–0.63, respectively). Similar associations were found for NSLLM versus GM for metastatic PC (HR 0.57, 95% CI: 0.41–0.79) and PC mortality (HR 0.66, 95% CI: 0.51–0.85).

      Conclusions

      Our analyses provide one of the more comprehensive findings to date that statins may reduce risk of metastatic PC and PC mortality, and the first to demonstrate that NSLLM have similar effects, supporting a cholesterol-based mechanism.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kearney P.M.
        • Blackwell L.
        • Collins R.
        • Keech A.
        • Simes J.
        • et al.
        • Cholesterol Treatment Trialists' (CTT) Collaborators
        Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
        Lancet. 2008; 371: 117-125
        • Tonelli M.
        • Lloyd A.
        • Clement F.
        • Conly J.
        • Husereau D.
        • Hemmelgarn B.
        • et al.
        Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis.
        CMAJ Can Med Assoc J. 2011; 183: E1189-E1202
        • Pelton K.
        • Freeman M.R.
        • Solomon K.R.
        Cholesterol and prostate cancer.
        Curr Opin Pharmacol. 2012; 12: 751-759
        • Solomon K.R.
        • Freeman M.R.
        Do the cholesterol-lowering properties of statins affect cancer risk?.
        Trends Endocrinol Metabol. 2008; 19: 113-121
        • Solomon K.R.
        • Freeman M.R.
        The complex interplay between cholesterol and prostate malignancy.
        Urol Clin North Am. 2011; 38: 243-259
        • Solomon K.R.
        • Pelton K.
        • Boucher K.
        • Joo J.
        • Tully C.
        • Zurakowski D.
        • et al.
        Ezetimibe is an inhibitor of tumor angiogenesis.
        Am J Pathol. 2009; 174: 1017-1026
        • Zhuang L.
        • Kim J.
        • Adam R.M.
        • Solomon K.R.
        • Freeman M.R.
        Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts.
        J Clin Invest. 2005; 115: 959-968
        • Baigent C.
        • Keech A.
        • Kearney P.M.
        • Blackwell L.
        • Buck G.
        • Pollicino C.
        • et al.
        Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
        Lancet. 2005; 366: 1267-1278
        • Browning D.R.
        • Martin R.M.
        Statins and risk of cancer: a systematic review and meta analysis.
        Int J Cancer. 2007; 120: 833-843
        • Allott E.H.
        • Farnan L.
        • Steck S.E.
        • Arab L.
        • Su L.J.
        • Mishel M.
        • et al.
        Statin use and prostate cancer aggressiveness: results from the population-based North Carolina-Louisiana prostate cancer project.
        Cancer Epidemiol Biomark Prev. 2016; 25: 670-677
        • Breau R.H.
        • Karnes R.J.
        • Jacobson D.J.
        • McGree M.E.
        • Jacobsen S.J.
        • Nehra A.
        • et al.
        The association between statin use and the diagnosis of prostate cancer in a population based cohort.
        J Urol. 2010; 184: 494-499
        • Farwell W.R.
        • D'Avolio L.W.
        • Scranton R.E.
        • Lawler E.V.
        • Gaziano J.M.
        Statins and prostate cancer diagnosis and grade in a veterans population.
        J Natl Cancer Inst. 2011; 103: 885-892
        • Jacobs E.J.
        • Rodriguez C.
        • Bain E.B.
        • Wang Y.
        • Thun M.J.
        • Calle E.E.
        Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort.
        Cancer Epidemiol Biomark Prev. 2007; 16: 2213-2217
        • Jespersen C.G.
        • Norgaard M.
        • Friis S.
        • Skriver C.
        • Borre M.
        Statin use and risk of prostate cancer: a Danish population-based case-control study, 1997–2010.
        Cancer Epidemiol. 2014; 38: 42-47
        • Murtola T.J.
        • Tammela T.L.
        • Lahtela J.
        • Auvinen A.
        Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study.
        Cancer Epidemiol Biomark Prev. 2007; 16: 2226-2232
        • Platz E.A.
        • Leitzmann M.F.
        • Visvanathan K.
        • Rimm E.B.
        • Stampfer M.J.
        • Willett W.C.
        • et al.
        Statin drugs and risk of advanced prostate cancer.
        J Natl Cancer Inst. 2006; 98: 1819-1825
        • Tan P.
        • Zhang C.
        • Wei S.Y.
        • Tang Z.
        • Gao L.
        • Yang L.
        • et al.
        Effect of statins type on incident prostate cancer risk: a meta-analysis and systematic review.
        Asian J Androl. 2017; 19: 666-671
        • Chang C.C.
        • Ho S.C.
        • Chiu H.F.
        • Yang C.Y.
        Statins increase the risk of prostate cancer: a population-based case-control study.
        Prostate. 2011; 71: 1818-1824
        • Fowke J.H.
        • Motley S.S.
        • Barocas D.A.
        • Cookson M.S.
        • Concepcion R.
        • Byerly S.
        • et al.
        The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer.
        Cancer Causes Contr. 2011; 22: 417-426
        • Emilsson L.
        • Garcia-Albeniz X.
        • Logan R.W.
        • Caniglia E.C.
        • Kalager M.
        • Hernan M.A.
        Examining bias in studies of statin treatment and survival in patients with cancer.
        JAMA Oncol. 2018; 4: 63-70
        • Meng Y.
        • Liao Y.B.
        • Xu P.
        • Wei W.R.
        • Wang J.
        Statin use and mortality of patients with prostate cancer: a meta-analysis.
        OncoTargets Ther. 2016; 9: 1689-1696
        • Lund J.L.
        • Richardson D.B.
        • Sturmer T.
        The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application.
        Curr Epidemiol Rep. 2015; 2: 221-228
        • Kantor E.D.
        • Lipworth L.
        • Fowke J.H.
        • Giovannucci E.L.
        • Mucci L.A.
        • Signorello L.B.
        Statin use and risk of prostate cancer: results from the Southern community cohort study.
        Prostate. 2015; 75: 1384-1393
        • Mucci L.A.
        • Kantoff P.W.
        Is the evidence sufficient to recommend statins for all men with prostate cancer?.
        J Clin Oncol. 2017; 35: 3272-3274
        • Glynn R.J.
        • Knight E.L.
        • Levin R.
        • Avorn J.
        Paradoxical relations of drug treatment with mortality in older persons.
        Epidemiology. 2001; 12: 682-689
        • Schneeweiss S.
        • Patrick A.R.
        • Sturmer T.
        • Brookhart M.A.
        • Avorn J.
        • Maclure M.
        • et al.
        Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results.
        Med Care. 2007; 45: S131-S142
      1. (AHRQ Publication No. 12(13)-EHC099)Velentgas P. Dreyer N.A. Nourjah P. Smith S.R. Torchia M.M. Developing a protocol for observational comparative effectiveness research: a user's guide. Agency for Healthcare Research and Quality, Rockville, MDJanuary 2013
        • Tan N.
        • Klein E.A.
        • Li J.
        • Moussa A.S.
        • Jones J.S.
        Statin use and risk of prostate cancer in a population of men who underwent biopsy.
        J Urol. 2011; 186: 86-90
        • Flick E.D.
        • Habel L.A.
        • Chan K.A.
        • Van Den Eeden S.K.
        • Quinn V.P.
        • Haque R.
        • et al.
        Statin use and risk of prostate cancer in the California Men's Health Study cohort.
        Cancer Epidemiol Biomark Prev. 2007; 16: 2218-2225
        • Schaffner C.P.
        Prostatic cholesterol metabolism: regulation and alteration.
        in: Alan R. The prostatic cell: structure and function. Liss, Inc., New York, NY1981: 279-324
        • Platz E.A.
        • Till C.
        • Goodman P.J.
        • Parnes H.L.
        • Figg W.D.
        • Albanes D.
        • et al.
        Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.
        Cancer Epidemiol Biomark Prev. 2009; 18: 2807-2813
        • Schnoeller T.J.
        • Jentzmik F.
        • Schrader A.J.
        • Steinestel J.
        Influence of serum cholesterol level and statin treatment on prostate cancer aggressiveness.
        Oncotarget. 2017; 8: 47110-47120
        • Cannon C.P.
        • Blazing M.A.
        • Giugliano R.P.
        • McCagg A.
        • White J.A.
        • Theroux P.
        • et al.
        Ezetimibe added to statin therapy after acute coronary syndromes.
        N Engl J Med. 2015; 372: 2387-2397
        • Ference B.A.
        • Ginsberg H.N.
        • Graham I.
        • Ray K.K.
        • Packard C.J.
        • Bruckert E.
        • et al.
        Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
        Eur Heart J. 2017; 38: 2459-2472
        • Lee B.H.
        • Taylor M.G.
        • Robinet P.
        • Smith J.D.
        • Schweitzer J.
        • Sehayek E.
        • et al.
        Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1.
        Cancer Res. 2013; 73: 1211-1218
        • Mostaghel E.A.
        • Solomon K.R.
        • Pelton K.
        • Freeman M.R.
        • Montgomery R.B.
        Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors.
        PLoS One. 2012; 7: e30062

      Linked Article

      • Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy
        European Journal of CancerVol. 112
        • Preview
          Before launching large clinical trials to confirm the effects of statins in improving outcomes among men with prostate cancer (PC), the most appropriate target patient population and the type of statins need to be clearly identified.
        • Full-Text
        • PDF
      • Statins use and prostate cancer mortality
        European Journal of CancerVol. 124
        • Preview
          The association between statins therapy and prostate cancer is extensively studied [1,2]. Recently, one cohort study conducted by Van Rompay et al. published in European Journal of Cancer demonstrated that statins use was associated with a lower mortality of prostate cancer than non-use (hazard ratio 0.73, 95% confidence interval 0.66–0.81) [3]. This result was compatible with another cohort study in Finland showing that statins use after prostate cancer diagnosis was associated with 20% reduced mortality of prostate cancer (hazard ratio 0.80, 95% confidence interval 0.65–0.98) [4].
        • Full-Text
        • PDF
      • Statins – No more cream for cancer
        European Journal of CancerVol. 112
        • Preview
          In this issue of the European Journal of Cancer, Shao et al. and Van Rompay et al. [1,2] report that statins and, in the latter manuscript, also non-statin lipid-lowering medications appear to improve prostate cancer outcomes, both by retrospective analyses. This adds to the large body of epidemiological studies suggesting a favourable role for statins on the clinical outcomes of men with prostate cancer, but the precise nature of the anticancer effect of these drugs remains controversial. Retrospective studies have an inherent bias because all these men received the statin (or any other lipid-lowering drug) for a medical condition that may influence their prognosis or receiving a statin could be a surrogate for being under more ‘intensive’ medical care.
        • Full-Text
        • PDF